DE68922394T2 - Rekombinante vakzine von flagellin. - Google Patents

Rekombinante vakzine von flagellin.

Info

Publication number
DE68922394T2
DE68922394T2 DE68922394T DE68922394T DE68922394T2 DE 68922394 T2 DE68922394 T2 DE 68922394T2 DE 68922394 T DE68922394 T DE 68922394T DE 68922394 T DE68922394 T DE 68922394T DE 68922394 T2 DE68922394 T2 DE 68922394T2
Authority
DE
Germany
Prior art keywords
recombinant
flagellin
epitope
proteins
fusion proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE68922394T
Other languages
English (en)
Other versions
DE68922394D1 (de
Inventor
William Marjarian
Bruce Stocker
Salete Newton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
Praxis Biologics Inc
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxis Biologics Inc, Leland Stanford Junior University filed Critical Praxis Biologics Inc
Application granted granted Critical
Publication of DE68922394D1 publication Critical patent/DE68922394D1/de
Publication of DE68922394T2 publication Critical patent/DE68922394T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE68922394T 1988-05-05 1989-05-05 Rekombinante vakzine von flagellin. Expired - Fee Related DE68922394T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19057088A 1988-05-05 1988-05-05
PCT/US1989/001932 WO1989010967A1 (en) 1988-05-05 1989-05-05 Recombinant flagellin vaccines

Publications (2)

Publication Number Publication Date
DE68922394D1 DE68922394D1 (de) 1995-06-01
DE68922394T2 true DE68922394T2 (de) 1995-10-05

Family

ID=22701885

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68922394T Expired - Fee Related DE68922394T2 (de) 1988-05-05 1989-05-05 Rekombinante vakzine von flagellin.

Country Status (10)

Country Link
EP (1) EP0419513B1 (de)
JP (1) JP2793673B2 (de)
AT (1) ATE121782T1 (de)
AU (1) AU637049B2 (de)
CA (1) CA1340817C (de)
DE (1) DE68922394T2 (de)
DK (1) DK263390A (de)
FI (1) FI104638B (de)
NO (1) NO302031B1 (de)
WO (1) WO1989010967A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171782B1 (en) 1987-11-18 2001-01-09 Chiron Corporation Antibody compositions to HCV and uses thereof
US5714596A (en) * 1987-11-18 1998-02-03 Chiron Corporation NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus
US5698390A (en) * 1987-11-18 1997-12-16 Chiron Corporation Hepatitis C immunoassays
US5712088A (en) * 1987-11-18 1998-01-27 Chiron Corporation Methods for detecting Hepatitis C virus using polynucleotides specific for same
US6861212B1 (en) 1987-11-18 2005-03-01 Chiron Corporation NANBV diagnostics and vaccines
EP0449958B9 (de) * 1988-12-19 2003-05-28 American Cyanamid Company Meningococcales klasse i-aussenmembranprotein-vakzin
US7118757B1 (en) 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
US6027729A (en) * 1989-04-20 2000-02-22 Chiron Corporation NANBV Diagnostics and vaccines
DK0551324T3 (da) * 1990-10-01 1998-01-26 Mini Agriculture & Fisheries Polynucleotidsekvens fra Salmonella
IE913455A1 (en) * 1990-10-01 1992-04-08 Mini Agriculture & Fisheries Method of testing for salmonella
GB9101550D0 (en) * 1991-01-24 1991-03-06 Mastico Robert A Antigen-presenting chimaeric protein
IL101639A0 (en) * 1992-04-17 1992-12-30 Yeda Res & Dev Recombinant influenza vaccines
EP1112747B1 (de) * 1999-12-28 2004-06-16 Akzo Nobel N.V. Salmonella Impfstoff, der keinen Antikörper gegen Flagellin oder gegen Flagella induziert
WO2004055045A1 (ja) * 2002-12-16 2004-07-01 Caf Laboratories Inc. サルモネラ抗原処方物、それを使用した抗体検査キット及びサブユニットワクチン
US20080248068A1 (en) 2004-05-07 2008-10-09 Hans-Gustaf Ljunggren Use of Flagellin as an Adjuvant for Vaccine
ATE518881T1 (de) * 2004-12-02 2011-08-15 Csir Grampositive bakterienzellen enthaltend ein unterbrochenes flagellingen, fusionsproteine auf flagellinbasis und deren verwendung zum entfernen von metallionen aus einer flüssigkeit
EP1827489B1 (de) 2004-12-16 2012-10-31 Wake Forest University Health Sciences Verwendung von flagellin zur tumorimmuntherapie
EP2374474A1 (de) 2005-01-19 2011-10-12 Vaxinnate Corporation Zusammensetzungen mit Pathogen-assoziierten Molekularstrukturen und Antigene sowie ihre Verwendungen zur Stimulation einer Immunantwort
ES2534332T3 (es) 2006-03-07 2015-04-21 Vaxinnate Corporation Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas
AU2009236585B2 (en) 2008-04-18 2013-03-07 Vaxinnate Corporation Deletion mutants of flagellin and methods of use
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
CN102816246B (zh) * 2012-09-04 2014-07-23 成都蓉生药业有限责任公司 一种人巨细胞病毒免疫原融合蛋白及其制备方法和用途
JP2017530114A (ja) 2014-09-26 2017-10-12 バヴァリアン・ノルディック・アクティーゼルスカブ フラジェリンをコードする組み換えｍｖａによる鼻腔内免疫のための方法と組成物
EP3221464B1 (de) * 2014-11-18 2022-02-23 The Trustees of Columbia University in the City of New York Detektion von analyten unter verwendung von lebenden zellen
CN104402974B (zh) * 2014-12-10 2017-11-14 重庆医科大学 一种具有粘膜免疫佐剂活性的多肽及其在制备粘膜免疫佐剂中的用途
US10849938B2 (en) 2017-09-13 2020-12-01 ZBiotics Company Gene expression system for probiotic microorganisms

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4735801A (en) * 1982-09-07 1988-04-05 Board Of Trustees Of Leland Stanford Jr. University Novel non-reverting salmonella live vaccines
JPS63501053A (ja) * 1985-10-11 1988-04-21 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド 異種タンパク質の生産方法
EP0237045B1 (de) * 1986-03-11 1993-10-20 Shionogi & Co., Ltd. Für Flagellin kodierende DNS und dieses enthaltender Vektor
CA1331355C (en) * 1986-04-21 1994-08-09 Bioenterprises Pty. Ltd Immunopotentation

Also Published As

Publication number Publication date
EP0419513B1 (de) 1995-04-26
CA1340817C (en) 1999-11-09
FI905441A0 (fi) 1990-11-02
AU637049B2 (en) 1993-05-20
NO904806L (no) 1991-01-03
FI104638B (fi) 2000-03-15
EP0419513A1 (de) 1991-04-03
NO302031B1 (no) 1998-01-12
ATE121782T1 (de) 1995-05-15
NO904806D0 (no) 1990-11-05
JPH04502402A (ja) 1992-05-07
AU3697989A (en) 1989-11-29
WO1989010967A1 (en) 1989-11-16
DE68922394D1 (de) 1995-06-01
DK263390A (da) 1991-01-04
JP2793673B2 (ja) 1998-09-03
DK263390D0 (da) 1990-11-02

Similar Documents

Publication Publication Date Title
DE68922394D1 (de) Rekombinante vakzine von flagellin.
EP2949340A1 (de) Impfstoffzusammensetzung gegen Streptococcus Suis-Infektion
WO2001091536A3 (en) Genetic vaccine that mimics natural viral infection and induces long-lasting immunity to pathogens
WO2005046621A3 (en) Enhancement of vaccine-induced immune responses and protection by heterologous boosting with alphavirus replicon vaccines
WO2000000216A3 (en) Use of poxviruses as enhancer of specific immunity
Bäckström et al. Insertion of a HIV-1-neutralizing epitope in a surface-exposed internal region of the cholera toxin B-subunit
WO2002074920A3 (en) A replication-defective alphavirus vaccine linking antigen with an immunogenicity-potentiating polypeptide and a method of delivery the same
CA2158024A1 (en) A mycoplasma gallisepticum antigen, dna encoding the antigen, recombinant vector bearing the dna and recombinant virus utilizing the recombinant vector as well as use thereof
NZ213303A (en) Plasmodium protein, dna sequence and vaccine
DE69739233D1 (de) Ein durch labile bindung an einen träger gebundenes antigen enthaltender impstoff
KR920006503A (ko) 살모넬라 백신 균주의 표면에 면역원성 말라리아 항원을 발현할수 있는 재조합 발현 벡터
Frenchick et al. Biochemical and immunological characterization of a novel peptide carrier system using rotavirus VP6 particles
FI953371A (fi) TBE-virusinfektiota vastaan tähtäävään immunisointiin tarkoitetut parannetut rokotteet sekä menetelmä niiden valmistamiseksi
Grosfeld et al. Delineation of protective epitopes on the E2-envelope glycoprotein of Semliki Forest virus
KR890000106A (ko) 원생성 기생충 예방용 백신
WO2002032453A1 (fr) Vaccin de synthese pour la lutte contre le virus de la peste porcine classique et son procede de preparation
WO2000063242A8 (en) Chimeric lyssavirus nucleic acids and polypeptides
DE3582422D1 (de) Biologische zubereitungen.
Jenkins et al. Enhanced delivery systems for enteric antigen uptake in teleosts
Smith et al. Potential for GTF-based synthetic peptides in a dental caries vaccine
Flores et al. Molecular cloning of rotaviral genes: Implications for immunoprophylaxis.
Arya Suppositories as carriers of epitopes to enteric and genital mucosal immune system
DE68912229T2 (de) Als Anti-Malaria-Impfstoff verwendbares immunologisch aktives Peptidkonjugat PPD-(NANP)n.
BEESLEY EXPRESSION OF HBCAG FUSION PROTEINS IN YEAST AND AN INVESTIGATION OF THEIR IMMUNOLOGICAL PROPERTIES (IMMUNOLOGY)
DK0388738T3 (da) Plasmodium merozoit rhoptries-antigen og derivater

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: AMERICAN CYANAMID CO., PORTLAND, ME., US THE BOARD

8339 Ceased/non-payment of the annual fee